Zobrazeno 1 - 10
of 337
pro vyhledávání: '"R Liesner"'
Autor:
Marjon H Cnossen, Frank W G Leebeek, Ron A A Mathôt, M Coppens, MJHA Kruip, S Polinder, K Fischer, R Liesner, K Fijnvandraat, Laura H Bukkems, PW Collins, P Chowdary, K Meijer, A Janssen, MH Cnossen, Jessica M Heijdra, Wala Al Arashi, Nico C B de Jager, Michael E Cloesmeijer, Christian M Zwaan, FWG Leebeek, RAA Mathôt, RYJ Tamminga, BAP Laros-van Gorkom, P Brons, SEM Schols, FJM van der Meer, HCJ Eikenboom, REG Schutgens, F Heubel-Moenen, L Nieuwenhuizen, P Ypma, MHE Driessens, CM Zwaan, I van Vliet, D Keeling, J Lock, HCAM Hazendonk, I van Moort, T Preijers, JM Heijdra, NCB de Jager, MCHJ Goedhart, LH Bukkems, W Al Arashi, ME Cloesmeijer
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/1965d1889ddf4cbeb8a1d66664e6a252
Autor:
Jessica M. Heijdra, Ferdows Atiq, Wala Al Arashi, Quincy Kieboom, Esmee Wuijster, Karina Meijer, Marieke J.H.A. Kruip, Frank W.G. Leebeek, Marjon H. Cnossen, K. Fijnvandraat, R.A.A. Mathôt, S. Polinder, M. Coppens, R.Y.J. Tamminga, K. Meijer, B.A.P. Laros‐van Gorkom, P. Brons, S.E.M. Schols, F.J.M. van der Meer, H.C.J. Eikenboom, R.E.G. Schutgens, K. Fischer, F. Heubel‐Moenen, L. Nieuwenhuizen, P. Ypma, M.H.E. Driessens, C.M. Zwaan, I. van Vliet, P.W. Collins, R. Liesner, P. Chowdary, D. Keeling, J. Lock, H.C.A.M. Hazendonk, I. van Moort, T. Preijers, N.C.B. de Jager, M.C.H.J. Goedhart, L.H. Bukkems, M.E. Cloesmeijer, A. Janssen
Publikováno v:
Research and practice in thrombosis and haemostasis, 6(6):e12784. Wiley-Blackwell Publishing Ltd
Research and Practice in Thrombosis and Haemostasis, 6(6):e12784. Wiley-Blackwell Publishing Ltd
Research and practice in thrombosis and haemostasis, 6(6):e12784. Wiley
Research and Practice in Thrombosis and Haemostasis, 6(6):e12784. Wiley-Blackwell Publishing Ltd
Research and practice in thrombosis and haemostasis, 6(6):e12784. Wiley
Background: Individuals with von Willebrand disease (VWD) require desmopressin testing because of interindividual response differences. However, testing is burdensome, while not all patients may need extensive testing.Objectives: To provide von Wille
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e0a565361a6f821a227ac15b88756ac
https://pure.amc.nl/en/publications/desmopressin-testing-in-von-willebrand-disease(e39b8cf5-28d9-4e8d-aaea-05ff14efa6d6).html
https://pure.amc.nl/en/publications/desmopressin-testing-in-von-willebrand-disease(e39b8cf5-28d9-4e8d-aaea-05ff14efa6d6).html
Autor:
R. Liesner, Erik Berntorp, Sharyne Donfield, Amy D. Shapiro, Munira Borhany, Stacy E. Croteau, Susan Kearney, Cristina Tarango, Christoph Bidlingmaier, Catherine E. McGuinn, Yasmina L. Abajas, Manuela Carvalho, Roshni Kulkarni, Jan Astermark, Petra LeBeau, Philip Kuriakose, Christine M. Knoll, Stefan Lethagen, Michelle Witkop, Katharina Holstein, Alice J. Cohen, Margaret V. Ragni, Suchitra S. Acharya, Johannes Oldenburg, Eva Funding, Ulrike M. Reiss, Christine L. Kempton, Michael D. Tarantino
Publikováno v:
Haemophilia. 27:49-59
Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.B-Natural is a multi-centre, prospective, observational stu
Autor:
Marjon H Cnossen, Frank W G Leebeek, Ron A A Mathôt, M Coppens, MJHA Kruip, S Polinder, K Fischer, R Liesner, K Fijnvandraat, Laura H Bukkems, PW Collins, P Chowdary, K Meijer, A Janssen, MH Cnossen, Jessica M Heijdra, Wala Al Arashi, Nico C B de Jager, Michael E Cloesmeijer, Christian M Zwaan, FWG Leebeek, RAA Mathôt, RYJ Tamminga, BAP Laros-van Gorkom, P Brons, SEM Schols, FJM van der Meer, HCJ Eikenboom, REG Schutgens, F Heubel-Moenen, L Nieuwenhuizen, P Ypma, MHE Driessens, CM Zwaan, I van Vliet, D Keeling, J Lock, HCAM Hazendonk, I van Moort, T Preijers, JM Heijdra, NCB de Jager, MCHJ Goedhart, LH Bukkems, W Al Arashi, ME Cloesmeijer
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
BMJ open, 12(2):e049493. BMJ Publishing Group
BMJ Open, 12(2):e049493. BMJ Publishing Group
BMJ open, 12(2):e049493. BMJ Publishing Group
BMJ Open, 12(2):e049493. BMJ Publishing Group
IntroductionVon Willebrand disease (VWD) is a bleeding disorder, caused by a deficiency or defect of von Willebrand factor (VWF). In case of medical procedures or bleeding, patients are treated with desmopressin and/or VWF-containing concentrates to
Autor:
R. Liesner, J. Bowen, Jan Astermark, Stacy E. Croteau, Susan Kearney, Suchitra S. Acharya, Amy D. Shapiro, Yasmina L. Abajas, Stefan Lethagen, Erik Berntorp, Eva Funding, Christine L. Kempton, Katharina Holstein, Petra LeBeau
Publikováno v:
Astermark, J, Holstein, K, Abajas, Y L, Kearney, S, Croteau, S E, Liesner, R, Funding, E, Kempton, C L, Acharya, S, Lethagen, S, LeBeau, P, Bowen, J, Berntorp, E & Shapiro, A D 2021, ' The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B ', Haemophilia, vol. 27, no. 5, pp. 802-813 . https://doi.org/10.1111/hae.14357
Introduction: Inhibitors develop less frequently in haemophilia B (HB) than haemophilia A (HA). However, when present, the success of tolerization by immune tolerance induction (ITI) therapy is lower and the risk of complications higher. Aim: To eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa0c22d8e969175b16a7f593d937ce99
https://curis.ku.dk/ws/files/285380734/hae.14357.pdf
https://curis.ku.dk/ws/files/285380734/hae.14357.pdf
Autor:
Peter William Collins, Michael Makris, C. L. Percy, Charles R. M. Hay, Pratima Chowdary, Kate Talks, Elizabeth Chalmers, Daniel P. Hart, R. Liesner, Georgina W. Hall, Anne Riddell
Publikováno v:
Haemophilia. 24:344-347
Emicizumab is a bispecific antibody that activates FX to FXa in the absence of FVIII. It has been shown to reduce bleeding episodes in people with haemophilia A complicated by a FVIII inhibitor. Despite the protection against bleeds, some breakthroug
Publikováno v:
Haemophilia. 24:941-949
Hereditary factor X (FX) deficiency (FXD) affects 1:500 000-1:1 000 000 people worldwide. A novel, high-purity plasma-derived FX concentrate (pdFX) is available in the United States and European Union as replacement therapy for FXD, but data are scar
Autor:
M. Jansen, R. Liesner, I. Dzhunova, Anna Klukowska, Sigurd Knaub, Johann Bichler, Tomasz Szczepański, Vladimir Vdovin
Publikováno v:
Haemophilia. 24:595-603
Introduction Nuwiq® (human-cl rhFVIII, simoctocog alfa) is a 4th generation recombinant human FVIII, without chemical modification or fusion with any other protein, produced in a human cell line. Aim/methods This study (GENA-13) was an extension of
Autor:
H Platokouki, Anne Rafowicz, Manuel Carcao, H. M. Van Den Berg, R. Liesner, Gili Kenet, Karin Kurnik, Samantha C. Gouw, Krista Fischer, Georges-Etienne Rivard
Publikováno v:
Haemophilia, 24(2), 283. Wiley-Blackwell
Haemophilia, 24(2), 283-290. Wiley-Blackwell
Haemophilia, 24(2), 283-290. Wiley-Blackwell
Background: Inhibitor development in previously untreated patients (PUPs) with severe haemophilia A is a multifactorial event. It is unknown whether paediatric vaccinations given in close proximity to factor VIII (FVIII) are associated with inhibitor
Autor:
John K. Wu, Leonid Dubey, R. Liesner, Michael Gattens, Larisa Belyanskaya, Marianne Sigaud, Olga Aleinikova, N. Kavardakova, Manuel Carcao, Carmen Altisent, Anthony K.C. Chan, Jonathan M. Ducore, Yves Gruel, Sigurd Knaub, M. Abashidze, N. A. Fouzia, Benoît Guillet, Hervé Chambost, M. Jansen, Thierry Lambert, Olaf Walter, M. El Khorassani, V. Turea, A. Borel-Derlon, Vladimir Vdovin, Sunil Lohade, Ellis J. Neufeld, Mark Belletrutti, A. Pavlova, Anna Klukowska
Publikováno v:
Haemophilia. 24:211-220
Introduction Nuwiq® (Human-cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein fusion. No inhibitors developed in studies with Nuwiq® in 201 previously treated patients with